List of Excipients in Branded Drug NORTREL

« Back to Dashboard

Generic Drugs Containing NORTREL

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	norethindrone and ethinyl estradiol	0555-9009	D&C YELLOW NO. 10 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	norethindrone and ethinyl estradiol	0555-9009	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	norethindrone and ethinyl estradiol	0555-9009	MAGNESIUM STEARATE
Teva Pharmaceuticals USA Inc	norethindrone and ethinyl estradiol	0555-9009	STARCH, CORN

What are the Most Frequently-Used Excipients in NORTREL?

# Of NDCs	Excipient
1	D&C YELLOW NO. 10 ALUMINUM LAKE
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	STARCH, CORN

NORTREL Excipient Strategy, Formulation Patents, and Commercial Opportunities

Last updated: September 26, 2026

NORTREL is a prescription combined oral contraceptive containing norethindrone and ethinyl estradiol. Its commercial opportunity is primarily generic and formulation-driven. The product has old active ingredients, no meaningful biosimilar exposure, and limited apparent patent protection around the marketed drug itself. Value is more likely to come from reliable low-dose manufacturing, differentiated excipient systems, packaging, supply continuity, and lifecycle products than from composition-of-matter patents.

What is NORTREL and which formulations are marketed?

NORTREL is marketed in several oral tablet configurations containing 35 mcg of ethinyl estradiol and different norethindrone doses. FDA-approved labeling identifies both monophasic and triphasic products.[1]

Product configuration	Norethindrone dose	Ethinyl estradiol dose	Pack format
NORTREL 0.5/35	0.5 mg	35 mcg	21-day or 28-day pack
NORTREL 1/35	1 mg	35 mcg	21-day or 28-day pack
NORTREL 7/7/7	0.5 mg, 0.75 mg, 1 mg	35 mcg	28-day pack

The 28-day products generally contain 21 active tablets and seven inert tablets. The inert tablets support adherence and calendar-based administration but do not contain the active hormonal ingredients.[1]

NORTREL is a small-molecule oral solid dosage product. It is not a biologic and therefore does not create a biosimilar substitution pathway under the Public Health Service Act.

What excipients are used in NORTREL tablets?

NORTREL excipients vary by product strength, manufacturer, tablet color, and regulatory filing. The principal excipient functions are:

Excipient function	Typical materials used in oral contraceptive tablets	Commercial purpose
Diluent	Lactose, microcrystalline cellulose, calcium phosphate	Provides tablet mass and improves content uniformity
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Supports granule and tablet strength
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Controls tablet breakup and dissolution
Lubricant	Magnesium stearate, stearic acid	Supports compression and ejection
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Coating system	Hypromellose, polyethylene glycol, titanium dioxide, iron oxides	Controls appearance, identification, and handling
Colorant	FDA-permitted dyes or lakes, iron oxides	Differentiates strengths and dosing phases

The practical formulation issue is not the total amount of excipient. It is the low dose of ethinyl estradiol relative to the tablet mass. A 35-mcg dose requires strong control of segregation, blend uniformity, sampling bias, and transfer losses. Excipient selection must support uniform distribution at low drug loading without creating excessive lubricant sensitivity or delayed dissolution.

FDA labeling should control the final excipient assessment for each specific NORTREL product. Different ANDA holders may use different excipient systems while meeting the same quality target.[1][2]

Which excipient strategies offer the strongest commercial opportunity?

The highest-value opportunities are excipients and processing systems that improve dose uniformity, dissolution robustness, stability, or manufacturing yield.

Direct-compression platforms

A direct-compression formulation can reduce manufacturing steps and lower exposure to solvent, heat, and drying variability. The key commercial requirements are:

• Consistent particle-size distribution.
• Low segregation tendency.
• Adequate flow at low-dose drug loading.
• Stable tablet hardness across production lots.
• Acceptable dissolution after storage.
• Compatibility with small tablet sizes and colored tablets.

Co-processed excipients may be attractive where they improve flow and compressibility without requiring a proprietary process change. Suppliers must demonstrate that the platform does not create new extractables, alter dissolution, or complicate post-approval change management.

Wet-granulation systems

Wet granulation can improve content uniformity when the active ingredients have poor flow or unfavorable particle-size characteristics. It also provides a more controlled route for distributing small quantities of ethinyl estradiol through the blend.

The commercial disadvantages are additional equipment, drying controls, longer cycle times, and greater process complexity. A granulation platform is most attractive where it improves yield or reduces blend-uniformity failures enough to justify the extra process step.

Dry-granulation and roller-compaction systems

Dry granulation can improve flow without introducing water or solvent. It may be useful for manufacturers seeking lower thermal or moisture exposure. The principal risks are ribbon-density variation, over-compaction, slower disintegration, and altered dissolution after milling.

A supplier with a robust roller-compaction excipient system could target generic oral contraceptive manufacturers that need consistent performance across multiple tablet strengths.

What formulation patents could protect a NORTREL product?

A conventional NORTREL tablet is unlikely to support a strong new composition-of-matter patent because norethindrone and ethinyl estradiol are established active ingredients. Patentable opportunities would more likely arise from a narrow formulation or manufacturing claim.

Potential claim categories include:

1. A defined excipient ratio that produces specified dissolution or stability results.
2. A low-dose blend process that improves ethinyl estradiol content uniformity.
3. A multilayer or coated tablet architecture.
4. A controlled-release formulation, although this would require clinical and regulatory support.
5. A packaging system that limits moisture, light, or hormonal degradation.
6. A manufacturing process that reduces content variability or improves yield.
7. A specific triphasic tablet arrangement and color-coding system.
8. A novel orally disintegrating, chewable, or highly compact dosage form.

Patent strength would depend on unexpected technical results, narrow claim drafting, reproducibility, and freedom-to-operate analysis against existing contraceptive formulations. A generic tablet using ordinary lactose, starch, magnesium stearate, and standard coating materials would usually have weak patent differentiation.

What is the Orange Book status of NORTREL?

NORTREL is a small-molecule prescription product generally associated with abbreviated new drug application competition rather than a current innovative-drug exclusivity model. The active ingredients have long commercial histories, and the primary market barrier is regulatory approval and manufacturing execution rather than a new chemical entity patent.

The FDA Orange Book records listed patents and exclusivities for approved products, but an Orange Book listing does not establish that every formulation or manufacturing feature is protected.[2] For NORTREL, commercial review should focus on:

• Whether a specific NORTREL product is listed as a reference listed drug.
• Whether any patent information is currently listed for that product.
• Whether a proposed ANDA must make Paragraph I, II, III, or IV certifications.
• Whether labeling, tablet appearance, or packaging creates a separate regulatory issue.
• Whether the target product is approved under an ANDA or another pathway.

A current, product-specific Orange Book search is required before relying on any patent-expiration date. No reliable commercial conclusion should use an assumed NORTREL patent number or expiration date.

When does NORTREL lose exclusivity?

NORTREL’s principal market exclusivity is not expected to depend on a remaining new-chemical-entity period. Generic competition is generally possible once the applicable reference-product and regulatory requirements are satisfied.

The relevant timing framework is:

Exclusivity or barrier	Relevance to NORTREL
New chemical entity exclusivity	Not a current commercial driver for these established ingredients
Five-year NCE patent protection	Not expected to apply to the historical active ingredients
Three-year clinical-investigation exclusivity	Product-specific and unlikely to be central to the established formulation
Pediatric exclusivity	Must be verified in the current FDA records
Orange Book patents	Must be checked by reference product and strength
ANDA approval	Primary route for generic competition
180-day first-filer exclusivity	Potentially relevant if a Paragraph IV filer exists and qualifies

Generic entry can still be delayed by bioequivalence failures, manufacturing deficiencies, supply constraints, labeling disputes, or inability to source a suitable reference product.

Which companies are challenging NORTREL patents?

There is no basis to identify a current NORTREL Paragraph IV challenger without a product-specific review of FDA records, patent certifications, and federal court dockets. Because NORTREL is a mature oral contraceptive, competition is more likely to involve multiple generic manufacturers than a single high-profile patent challenge.

A competitive diligence review should examine:

• FDA Orange Book patent listings.
• FDA Paragraph IV notice activity.
• ANDA approvals for norethindrone and ethinyl estradiol tablets.
• Abbreviated new drug application litigation under the Hatch-Waxman Act.
• Product discontinuation records.
• Manufacturer recalls and warning letters.
• Current wholesaler and pharmacy availability.

How strong is the NORTREL patent estate?

The apparent patent estate is weak around the basic active-ingredient combination and stronger only where a sponsor develops a technically differentiated formulation or process.

Asset type	Likely strength for conventional NORTREL	Commercial assessment
Active ingredient patent	Very low	Ingredients are established
Basic tablet composition	Low	Common excipients are difficult to defend broadly
Low-dose uniformity process	Moderate if supported by data	Possible manufacturing advantage
Triphasic tablet architecture	Moderate to low	Design-around risk is high
Stability-enhancing packaging	Moderate	Can protect a narrow commercial configuration
Modified-release formulation	Potentially strong	Requires substantial development and regulatory support
Trademark and trade dress	Limited	Protects branding, not generic substitution
Manufacturing know-how	Moderate	May remain valuable even without patent protection

Trade secrets may provide more durable value than patents for blending order, sampling plans, granulation endpoints, coating parameters, and scale-up controls.

What commercial opportunities exist for excipient suppliers and manufacturers?

The strongest opportunities are in supply reliability and quality performance rather than premium pricing based solely on excipient identity.

Excipient suppliers

Suppliers can target:

• Low-dose direct-compression platforms.
• Co-processed excipients for improved blend uniformity.
• Low-moisture formulations.
• Color-compatible coating systems.
• Excipient systems that reduce tablet weight.
• Materials with robust global regulatory support.
• Supply agreements with dual-source qualification.

Regulatory documentation is a sales differentiator. Suppliers should support drug-master-file access, elemental impurity data, nitrosamine risk assessments where relevant, residual-solvent information, allergen statements, and change-notification controls.

Generic manufacturers

Manufacturers can compete through:

• Multiple strengths in one manufacturing platform.
• 21-day and 28-day pack configurations.
• Reliable pharmacy-channel supply.
• Improved tablet appearance and patient identification.
• Lower tablet weight.
• Reduced packaging cost.
• Contract manufacturing for private-label contraceptive products.
• Regional registration using a common formulation architecture.

The most defensible product may be a platform that covers NORTREL 0.5/35, 1/35, and 7/7/7 while maintaining acceptable uniformity and dissolution across different hormone loads.

What generic launch risks exist for NORTREL?

The main risks are operational and regulatory.

Content uniformity

Ethinyl estradiol is present at a very low dose. Poor dispersion can cause out-of-specification results, process validation failures, and costly batch rejection.

Dissolution variability

Changes in lubricant concentration, compression force, granule density, or coating weight can affect dissolution. A formulation that passes initial testing may lose robustness after scale-up.

Tablet identification

Triphasic products require reliable color and phase differentiation. Colorant changes, coating variation, and packaging errors can create medication-use risk.

Packaging and adherence

The seven inert tablets in 28-day packs are part of the adherence design. Pack configuration, labeling, calendar orientation, and tablet order must remain consistent with the approved labeling.

Manufacturing changes

Excipient substitutions may trigger post-approval reporting obligations and comparability work. The least expensive excipient is not necessarily the lowest-cost option after validation, stability, and regulatory change-control costs are included.

How does NORTREL compare with other oral contraceptive products?

NORTREL competes with other combined oral contraceptives containing ethinyl estradiol and a progestin, including products based on levonorgestrel, norgestimate, desogestrel, and drospirenone. Its differentiation is constrained because physicians and payers often view mature oral contraceptives as substitutable within formulary and therapeutic categories.

Factor	NORTREL	Newer branded contraceptive
Active ingredients	Established	May use newer progestin or delivery technology
Patent position	Generally limited	Potentially stronger
Generic competition	High	Depends on remaining patents
Excipient opportunity	Manufacturing efficiency and reliability	Product differentiation and lifecycle claims
Biosimilar risk	None	None for small molecules
Pricing power	Usually limited	Higher if brand differentiation remains
Commercial moat	Supply, quality, distribution, branding	Patents, clinical differentiation, delivery system

NORTREL is therefore better suited to a cost-efficient generic or private-label strategy than to a high-margin innovative formulation strategy unless a new delivery system is developed.

What is the revenue exposure and licensing opportunity?

Standalone NORTREL revenue is generally not disclosed separately by manufacturers. Public company reporting may combine oral contraceptive sales with broader women’s-health or generic portfolios. Revenue exposure should therefore be estimated from unit volume, net price, channel mix, and manufacturer share rather than from reported NORTREL brand revenue.

Licensing opportunities may include:

• Excipient platform licensing.
• Contract development and manufacturing.
• Regional rights for approved generic products.
• Private-label packaging and distribution.
• Co-development of modified-release or adherence-oriented products.
• Technology transfer for triphasic tablet manufacturing.

A standard excipient license has limited value unless it produces measurable benefits in yield, uniformity, stability, or tablet size. A manufacturing platform with validated performance across multiple NORTREL strengths has greater commercial leverage.

Key Takeaways

• NORTREL is a mature norethindrone and ethinyl estradiol oral contraceptive platform.
• The principal opportunity is generic manufacturing efficiency, not basic active-ingredient patent protection.
• Low-dose ethinyl estradiol creates the central formulation challenge: blend uniformity and process control.
• Direct compression, wet granulation, and dry granulation each have viable roles depending on powder properties and scale.
• Formulation patents are possible but should rely on defined technical effects, not ordinary excipient combinations.
• Biosimilar risk does not apply because NORTREL is a small-molecule drug.
• Orange Book, Paragraph IV, and patent-expiration conclusions must be made at the specific product and reference-listing level.
• The strongest commercial moat is likely to be manufacturing know-how, supply reliability, regulatory execution, and multi-strength platform capability.
• Revenue and licensing assessments should use product-level volume and pricing data because standalone NORTREL revenue is not generally reported.

FAQs

Can a new excipient create a patentable NORTREL product?

Yes, but the excipient must support a novel and non-obvious formulation or manufacturing result. A routine substitution of lactose, starch, or magnesium stearate is unlikely to provide strong patent protection.

Is NORTREL eligible for an over-the-counter switch?

NORTREL is a prescription combined oral contraceptive. An OTC switch would require a separate FDA review of the active ingredients, labeling, user comprehension, and self-selection profile. It should not be assumed from the product’s long commercial history.

What is the best excipient for NORTREL content uniformity?

No single excipient is universally superior. The outcome depends on active-particle size, drug loading, blending sequence, granulation method, compression process, and sampling design.

Can a manufacturer use a different excipient formula for a NORTREL generic?

Yes. An ANDA product may use a different inactive-ingredient system if it meets applicable FDA requirements and demonstrates pharmaceutical equivalence, bioequivalence, quality, and acceptable labeling.

Are triphasic NORTREL tablets harder to manufacture than monophasic tablets?

Yes. Triphasic products require control of three active-dose phases, tablet identification, phase sequencing, packaging accuracy, and consistent dissolution across each phase.

References

1. U.S. Food and Drug Administration. (n.d.). Norethindrone and ethinyl estradiol tablets, USP: Prescribing information for NORTREL. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.